This category features expert opinion on the latest developments in the field of cancer
Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort,…
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam…
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant,…
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr.…
By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors…
Author: Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor At UW/Fred Hutch,…
Author: Lei Deng, MD PGY-6 Fellow of Hematology/Oncology - Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor at UW/Fred Hutch,…
By Dr. Chepsy Philip Believer's Church Medical College Hospital Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the…